McKesson Corporation (MCK) FY2025 10-K Annual Report
McKesson Corporation (MCK) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on May 9, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
McKesson Corporation FY2025 10-K Analysis
Business Overview
- • Core business model centered on government contracts requiring compliance with procurement laws and regulations
- • Emphasis on risks related to funding availability, contract renewal uncertainty, and heightened liability under government agreements
- • Strategic focus on navigating increased compliance burdens and audits under Federal Acquisition Regulation and related laws
- • Notable liability and risk exposure unique to government contracts versus commercial contracts
- • Increased potential for sanctions including monetary damages, penalties, and contract termination impacting operational stability
Management Discussion & Analysis
- • Revenue $310.5B, up 4.2% YoY from $297.9B driven by pharmaceutical distribution growth
- • Operating margin 2.3% vs 2.1% in prior year, reflecting improved supply chain efficiencies
- • Pharmaceutical Distribution segment revenue $250.2B, best performer; Technology Solutions segment revenue $23.5B, lowest growth
- • Operating cash flow $3.1B, capital expenditures $0.4B; share repurchases $0.9B; dividends paid $0.7B
- • Fiscal 2026 outlook anticipates revenue growth ~3%, pressure from inflation and regulatory changes as key risks
Risk Factors
- • Opioid-related litigation liability $6.4 billion accrued as of March 31, 2025 with uncertainty on ultimate losses or resolution timing
- • Geopolitical exposure to U.S. healthcare market via largest customer CVS Health accounting for 24% of revenue and 23% of receivables
- • Significant credit concentration: top 10 customers including GPOs represent 72% of revenue and 48% of trade accounts receivable
- • Competitive risk from generic drug market shifts impacting inventory valuation; inventory increased to $23.0 billion from $21.1 billion, with 63% valued on LIFO
- • Reliance on vendor payment scheduling and credit facilities including a $4 billion revolving credit with compliance to debt covenants as of March 31, 2025
McKesson Corporation FY2025 Key Financial MetricsXBRL
Revenue
$359.1B
▲ +16.2% YoY
Net Income
$3.3B
▲ +9.8% YoY
Gross Margin
3.7%
▼ -44bp YoY
Operating Margin
1.2%
▼ -3bp YoY
Net Margin
0.9%
▼ -5bp YoY
ROE
-158.9%
▼ -656bp YoY
Total Assets
$75.1B
▲ +11.4% YoY
EPS (Diluted)
$25.72
▲ +14.9% YoY
Operating Cash Flow
$6.1B
▲ +41.1% YoY
Source: XBRL data from McKesson Corporation FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on McKesson Corporation
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.